Skip to main content
Erschienen in: Zeitschrift für Rheumatologie 8/2021

17.09.2021 | Entzündlich-rheumatische Erkrankungen | Leitthema

Erkenntnisse zu Schwangerschaft und Stillzeit bei entzündlich rheumatischen Erkrankungen durch Beobachtungsdaten

verfasst von: Dr. Yvette Meißner, PD Dr. med. Anja Strangfeld

Erschienen in: Zeitschrift für Rheumatologie | Ausgabe 8/2021

Einloggen, um Zugang zu erhalten

Zusammenfassung

Informationen zu Schwangerschaft und Stillzeit bei Frauen mit chronischen entzündlich rheumatischen Erkrankungen sind sowohl für eine erfolgreiche Schwangerschaft als auch für die mütterliche und kindliche Gesundheit relevant. Da Schwangere und Stillende von randomisierten klinischen Studien meist ausgeschlossen sind, muss die Evidenz für die klinische Betreuung und Beratung aus Beobachtungsstudien generiert werden. In den vergangenen Jahrzehnten wurden hierfür neben den bestehenden Spontanmeldesystemen der Arzneimittelbehörden verschiedene Datensammlungen aufgebaut, mit dem Ziel das teratogene Risiko eines Arzneimittels zu überwachen. Zunehmend werden für die Erforschung schwangerschaftsassoziierter Ereignisse auch Versichertendaten, elektronische Krankenakten und skandinavische Register eingesetzt. Allen diesen Datenquellen fehlt aber die Einbeziehung der mütterlichen Erkrankung, besonders hinsichtlich ihrer inflammatorischen Komponente. Etablierte Kohortenstudien, Biologika- und Krankheitsregister erheben zwar die Krankheitsaktivität, sind aber nicht für schwangerschaftsspezifische Fragestellungen konzipiert. Schwangerschaftsregister und -studien in der Rheumatologie schließen diese Lücke. Um die Möglichkeiten und Limitationen vorhandener Datenquellen zu Schwangerschaft und Stillzeit besser einschätzen zu können, werden sie in der folgenden Übersichtsarbeit mit ihren jeweiligen Vor- und Nachteilen als auch Beispielen aus der Rheumatologie ausführlich vorgestellt. Zudem werden bestehende Kooperationen sowie Studien zur Untersuchung des Einflusses einer väterlichen rheumatischen Erkrankung beleuchtet.
Literatur
1.
Zurück zum Zitat RKI (2012) Daten und Fakten: Ergebnisse der Studie „Gesundheit in Deutschland aktuell 2010“. In: GBE-Hefte, S 1–188 RKI (2012) Daten und Fakten: Ergebnisse der Studie „Gesundheit in Deutschland aktuell 2010“. In: GBE-Hefte, S 1–188
2.
Zurück zum Zitat Kersten I, Lange AE, Haas JP et al (2014) Chronic diseases in pregnant women: prevalence and birth outcomes based on the SNiP-study. BMC Pregnancy Childbirth 14:75CrossRefPubMedPubMedCentral Kersten I, Lange AE, Haas JP et al (2014) Chronic diseases in pregnant women: prevalence and birth outcomes based on the SNiP-study. BMC Pregnancy Childbirth 14:75CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Lange U, Schnepp W, Zu Sayn-Wittgenstein F (2015) The experiences of chronically ill women in the time of pregnancy, birth and postnatal period—a review of qualitative studies. Z Geburtshilfe Neonatol 219(4):161–169CrossRefPubMed Lange U, Schnepp W, Zu Sayn-Wittgenstein F (2015) The experiences of chronically ill women in the time of pregnancy, birth and postnatal period—a review of qualitative studies. Z Geburtshilfe Neonatol 219(4):161–169CrossRefPubMed
4.
Zurück zum Zitat HMA (2019) Guideline on good pharmacovigilance practices (GVP). EMA/653036/2019:1–27. Draft for Public Consultation HMA (2019) Guideline on good pharmacovigilance practices (GVP). EMA/653036/2019:1–27. Draft for Public Consultation
5.
Zurück zum Zitat Levy RA, Vilela VS, Cataldo MJ et al (2001) Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study. Lupus 10(6):401–404CrossRefPubMed Levy RA, Vilela VS, Cataldo MJ et al (2001) Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study. Lupus 10(6):401–404CrossRefPubMed
6.
Zurück zum Zitat Hamulyak EN, Scheres LJJ, Goddijn M et al (2021) Antithrombotic therapy to prevent recurrent pregnancy loss in antiphospholipid syndrome-what is the evidence? J Thromb Haemost 19(5):1174–1185CrossRefPubMedPubMedCentral Hamulyak EN, Scheres LJJ, Goddijn M et al (2021) Antithrombotic therapy to prevent recurrent pregnancy loss in antiphospholipid syndrome-what is the evidence? J Thromb Haemost 19(5):1174–1185CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Weber-Schoendorfer C (2019) Sicherheit von Antirheumatika in der Schwangerschaft: Empfehlungen von Embryotox. Arthritis Rheuma 39(04):226–233CrossRef Weber-Schoendorfer C (2019) Sicherheit von Antirheumatika in der Schwangerschaft: Empfehlungen von Embryotox. Arthritis Rheuma 39(04):226–233CrossRef
8.
Zurück zum Zitat Langhoff-Roos J, Krebs L, Klungsoyr K et al (2014) The Nordic medical birth registers—a potential goldmine for clinical research. Acta Obstet Gynecol Scand 93(2):132–137CrossRefPubMed Langhoff-Roos J, Krebs L, Klungsoyr K et al (2014) The Nordic medical birth registers—a potential goldmine for clinical research. Acta Obstet Gynecol Scand 93(2):132–137CrossRefPubMed
9.
Zurück zum Zitat Wallenius M, Skomsvoll JF, Irgens LM et al (2012) Parity in patients with chronic inflammatory arthritides childless at time of diagnosis. Scand J Rheumatol 41(3):202–207CrossRefPubMed Wallenius M, Skomsvoll JF, Irgens LM et al (2012) Parity in patients with chronic inflammatory arthritides childless at time of diagnosis. Scand J Rheumatol 41(3):202–207CrossRefPubMed
10.
Zurück zum Zitat Harris N, Eudy A, Clowse M (2019) Patient-reported disease activity and adverse pregnancy outcomes in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Care Res 71(3):390–397CrossRef Harris N, Eudy A, Clowse M (2019) Patient-reported disease activity and adverse pregnancy outcomes in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Care Res 71(3):390–397CrossRef
11.
Zurück zum Zitat Zbinden A, van den Brandt S, Ostensen M et al (2018) Risk for adverse pregnancy outcome in axial spondyloarthritis and rheumatoid arthritis: disease activity matters. Rheumatology 57(7):1235–1242CrossRefPubMed Zbinden A, van den Brandt S, Ostensen M et al (2018) Risk for adverse pregnancy outcome in axial spondyloarthritis and rheumatoid arthritis: disease activity matters. Rheumatology 57(7):1235–1242CrossRefPubMed
12.
Zurück zum Zitat Murray K, Moore L, McAuliffe F et al (2019) Reproductive health outcomes in women with psoriatic arthritis. Ann Rheum Dis 78(6):850–852CrossRefPubMed Murray K, Moore L, McAuliffe F et al (2019) Reproductive health outcomes in women with psoriatic arthritis. Ann Rheum Dis 78(6):850–852CrossRefPubMed
13.
Zurück zum Zitat de Man YA, Hazes JM, van de Geijn FE et al (2007) Measuring disease activity and functionality during pregnancy in patients with rheumatoid arthritis. Arthritis Rheum 57(5):716–722CrossRefPubMed de Man YA, Hazes JM, van de Geijn FE et al (2007) Measuring disease activity and functionality during pregnancy in patients with rheumatoid arthritis. Arthritis Rheum 57(5):716–722CrossRefPubMed
14.
Zurück zum Zitat Buyon JP, Kim MY, Guerra MM et al (2015) Predictors of pregnancy outcomes in patients with lupus: a cohort study. Ann Intern Med 163(3):153–163CrossRefPubMedPubMedCentral Buyon JP, Kim MY, Guerra MM et al (2015) Predictors of pregnancy outcomes in patients with lupus: a cohort study. Ann Intern Med 163(3):153–163CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Meissner Y, Strangfeld A, Costedoat-Chalumeau N et al (2019) European Network of Pregnancy Registers in Rheumatology (EuNeP)-an overview of procedures and data collection. Arthritis Res Ther 21(1):241CrossRefPubMedPubMedCentral Meissner Y, Strangfeld A, Costedoat-Chalumeau N et al (2019) European Network of Pregnancy Registers in Rheumatology (EuNeP)-an overview of procedures and data collection. Arthritis Res Ther 21(1):241CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Chambers CD, Johnson DL, Xu R et al (2019) Birth outcomes in women who have taken adalimumab in pregnancy: a prospective cohort study. PLoS ONE 14(10):e223603CrossRefPubMedPubMedCentral Chambers CD, Johnson DL, Xu R et al (2019) Birth outcomes in women who have taken adalimumab in pregnancy: a prospective cohort study. PLoS ONE 14(10):e223603CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Cassina M, Johnson DL, Robinson LK et al (2012) Pregnancy outcome in women exposed to leflunomide before or during pregnancy. Arthritis Rheum 64(7):2085–2094CrossRefPubMed Cassina M, Johnson DL, Robinson LK et al (2012) Pregnancy outcome in women exposed to leflunomide before or during pregnancy. Arthritis Rheum 64(7):2085–2094CrossRefPubMed
18.
Zurück zum Zitat Smith CJF, Bandoli G, Kavanaugh A et al (2020) Birth outcomes and disease activity during pregnancy in a prospective cohort of women with psoriatic arthritis and ankylosing spondylitis. Arthritis Care Res 72(7):1029–1037CrossRef Smith CJF, Bandoli G, Kavanaugh A et al (2020) Birth outcomes and disease activity during pregnancy in a prospective cohort of women with psoriatic arthritis and ankylosing spondylitis. Arthritis Care Res 72(7):1029–1037CrossRef
19.
Zurück zum Zitat Forger F, Bandoli G, Luo Y et al (2019) No association of discontinuing tumor necrosis factor inhibitors before gestational week twenty in well-controlled rheumatoid arthritis and juvenile idiopathic arthritis with a disease worsening in late pregnancy. Arthritis Rheumatol 71(6):901–907CrossRefPubMed Forger F, Bandoli G, Luo Y et al (2019) No association of discontinuing tumor necrosis factor inhibitors before gestational week twenty in well-controlled rheumatoid arthritis and juvenile idiopathic arthritis with a disease worsening in late pregnancy. Arthritis Rheumatol 71(6):901–907CrossRefPubMed
20.
Zurück zum Zitat Clowse ME, Wolf DC, Forger F et al (2015) Pregnancy outcomes in subjects exposed to certolizumab pegol. J Rheumatol 42(12):2270–2278CrossRefPubMed Clowse ME, Wolf DC, Forger F et al (2015) Pregnancy outcomes in subjects exposed to certolizumab pegol. J Rheumatol 42(12):2270–2278CrossRefPubMed
21.
Zurück zum Zitat Warren RB, Reich K, Langley RG et al (2018) Secukinumab in pregnancy: outcomes in psoriasis, psoriatic arthritis and ankylosing spondylitis from the global safety database. Br J Dermatol 179(5):1205–1207CrossRefPubMed Warren RB, Reich K, Langley RG et al (2018) Secukinumab in pregnancy: outcomes in psoriasis, psoriatic arthritis and ankylosing spondylitis from the global safety database. Br J Dermatol 179(5):1205–1207CrossRefPubMed
22.
Zurück zum Zitat Weber-Schoendorfer C, Oppermann M, Wacker E et al (2015) Pregnancy outcome after TNF-alpha inhibitor therapy during the first trimester: a prospective multicentre cohort study. Br J Clin Pharmacol 80(4):727–739CrossRefPubMedPubMedCentral Weber-Schoendorfer C, Oppermann M, Wacker E et al (2015) Pregnancy outcome after TNF-alpha inhibitor therapy during the first trimester: a prospective multicentre cohort study. Br J Clin Pharmacol 80(4):727–739CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Weber-Schoendorfer C, Chambers C, Wacker E et al (2014) Pregnancy outcome after methotrexate treatment for rheumatic disease prior to or during early pregnancy: a prospective multicenter cohort study. Arthritis Rheumatol 66(5):1101–1110CrossRefPubMed Weber-Schoendorfer C, Chambers C, Wacker E et al (2014) Pregnancy outcome after methotrexate treatment for rheumatic disease prior to or during early pregnancy: a prospective multicenter cohort study. Arthritis Rheumatol 66(5):1101–1110CrossRefPubMed
24.
Zurück zum Zitat Clowse ME, Feldman SR, Isaacs JD et al (2016) Pregnancy outcomes in the tofacitinib safety databases for rheumatoid arthritis and psoriasis. Drug Saf 39(8):755–762CrossRefPubMedPubMedCentral Clowse ME, Feldman SR, Isaacs JD et al (2016) Pregnancy outcomes in the tofacitinib safety databases for rheumatoid arthritis and psoriasis. Drug Saf 39(8):755–762CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Hoeltzenbein M, Beck E, Rajwanshi R et al (2016) Tocilizumab use in pregnancy: analysis of a global safety database including data from clinical trials and post-marketing data. Semin Arthritis Rheum 46(2):238–245CrossRefPubMed Hoeltzenbein M, Beck E, Rajwanshi R et al (2016) Tocilizumab use in pregnancy: analysis of a global safety database including data from clinical trials and post-marketing data. Semin Arthritis Rheum 46(2):238–245CrossRefPubMed
26.
Zurück zum Zitat Petri M, Daly RP, Pushparajah DS (2015) Healthcare costs of pregnancy in systemic lupus erythematosus: retrospective observational analysis from a US health claims database. J Med Econ 18(11):967–973CrossRefPubMed Petri M, Daly RP, Pushparajah DS (2015) Healthcare costs of pregnancy in systemic lupus erythematosus: retrospective observational analysis from a US health claims database. J Med Econ 18(11):967–973CrossRefPubMed
27.
Zurück zum Zitat Joo YB, Kim KJ, Park KS et al (2020) Pregnancy rates and perinatal outcomes in women with systemic lupus erythematosus: data from the Korean national health claims database. Clin Rheumatol 40(6):2243–2250CrossRefPubMed Joo YB, Kim KJ, Park KS et al (2020) Pregnancy rates and perinatal outcomes in women with systemic lupus erythematosus: data from the Korean national health claims database. Clin Rheumatol 40(6):2243–2250CrossRefPubMed
28.
Zurück zum Zitat Kishore S, Mittal V, Majithia V (2019) Obstetric outcomes in women with rheumatoid arthritis: results from Nationwide Inpatient Sample Database 2003–2011(). Semin Arthritis Rheum 49(2):236–240CrossRefPubMed Kishore S, Mittal V, Majithia V (2019) Obstetric outcomes in women with rheumatoid arthritis: results from Nationwide Inpatient Sample Database 2003–2011(). Semin Arthritis Rheum 49(2):236–240CrossRefPubMed
29.
Zurück zum Zitat Wallenius M, Salvesen KA, Daltveit AK et al (2014) Rheumatoid arthritis and outcomes in first and subsequent births based on data from a national birth registry. Acta Obstet Gynecol Scand 93(3):302–307CrossRefPubMed Wallenius M, Salvesen KA, Daltveit AK et al (2014) Rheumatoid arthritis and outcomes in first and subsequent births based on data from a national birth registry. Acta Obstet Gynecol Scand 93(3):302–307CrossRefPubMed
30.
Zurück zum Zitat Mork S, Voss A, Moller S et al (2021) Spondyloarthritis and outcomes in pregnancy and labor: a nationwide register-based cohort study. Arthritis Care Res 73(2):282–288CrossRef Mork S, Voss A, Moller S et al (2021) Spondyloarthritis and outcomes in pregnancy and labor: a nationwide register-based cohort study. Arthritis Care Res 73(2):282–288CrossRef
31.
Zurück zum Zitat Drechsel P, Studemann K, Niewerth M et al (2020) Pregnancy outcomes in DMARD-exposed patients with juvenile idiopathic arthritis-results from a JIA biologic registry. Rheumatology 59(3):603–612PubMed Drechsel P, Studemann K, Niewerth M et al (2020) Pregnancy outcomes in DMARD-exposed patients with juvenile idiopathic arthritis-results from a JIA biologic registry. Rheumatology 59(3):603–612PubMed
32.
Zurück zum Zitat Pons M, Dougados M, Costedoat-Chalumeau N et al (2021) Pregnancy rates and outcomes in early axial spondyloarthritis: an analysis of the DESIR cohort. Joint Bone Spine 88(2):105075CrossRefPubMed Pons M, Dougados M, Costedoat-Chalumeau N et al (2021) Pregnancy rates and outcomes in early axial spondyloarthritis: an analysis of the DESIR cohort. Joint Bone Spine 88(2):105075CrossRefPubMed
33.
Zurück zum Zitat Ursin K, Lydersen S, Skomsvoll JF et al (2020) Factors associated with time to pregnancy in women with axial spondyloarthritis: A registry-based multicenter study. Arthritis Care Res (Hoboken) 73(8):1201–1209CrossRef Ursin K, Lydersen S, Skomsvoll JF et al (2020) Factors associated with time to pregnancy in women with axial spondyloarthritis: A registry-based multicenter study. Arthritis Care Res (Hoboken) 73(8):1201–1209CrossRef
34.
Zurück zum Zitat Gotestam Skorpen C, Hoeltzenbein M, Tincani A et al (2016) The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis 75(5):795–810CrossRefPubMed Gotestam Skorpen C, Hoeltzenbein M, Tincani A et al (2016) The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis 75(5):795–810CrossRefPubMed
35.
Zurück zum Zitat Meissner Y, Fischer-Betz R, Andreoli L et al (2021) EULAR recommendations for a core data set for pregnancy registries in rheumatology. Ann Rheum Dis 80(1):49–56CrossRefPubMed Meissner Y, Fischer-Betz R, Andreoli L et al (2021) EULAR recommendations for a core data set for pregnancy registries in rheumatology. Ann Rheum Dis 80(1):49–56CrossRefPubMed
36.
Zurück zum Zitat Broms G, Haerskjold A, Granath F et al (2018) Effect of maternal psoriasis on pregnancy and birth outcomes: a population-based cohort study from Denmark and Sweden. Acta Derm Venereol 98(8):728–734CrossRefPubMed Broms G, Haerskjold A, Granath F et al (2018) Effect of maternal psoriasis on pregnancy and birth outcomes: a population-based cohort study from Denmark and Sweden. Acta Derm Venereol 98(8):728–734CrossRefPubMed
37.
Zurück zum Zitat Broms G, Kieler H, Ekbom A et al (2020) Anti-TNF treatment during pregnancy and birth outcomes: a population-based study from Denmark, Finland, and Sweden. Pharmacoepidemiol Drug Saf 29(3):316–327CrossRefPubMed Broms G, Kieler H, Ekbom A et al (2020) Anti-TNF treatment during pregnancy and birth outcomes: a population-based study from Denmark, Finland, and Sweden. Pharmacoepidemiol Drug Saf 29(3):316–327CrossRefPubMed
38.
Zurück zum Zitat Tucker FD, Morris JK, Committee JRCM et al (2018) EUROCAT: an update on its functions and activities. J Community Genet 9(4):407–410CrossRefPubMedPubMedCentral Tucker FD, Morris JK, Committee JRCM et al (2018) EUROCAT: an update on its functions and activities. J Community Genet 9(4):407–410CrossRefPubMedPubMedCentral
39.
Zurück zum Zitat Plauborg AV, Hansen AV, Garne E (2016) Use of azathioprine and corticosteroids during pregnancy and birth outcome in women diagnosed with inflammatory bowel disease. Birth Defects Res Part A Clin Mol Teratol 106(6):494–499CrossRef Plauborg AV, Hansen AV, Garne E (2016) Use of azathioprine and corticosteroids during pregnancy and birth outcome in women diagnosed with inflammatory bowel disease. Birth Defects Res Part A Clin Mol Teratol 106(6):494–499CrossRef
40.
Zurück zum Zitat Palmsten K, Bandoli G, Watkins J et al (2021) Oral corticosteroids and risk of preterm birth in the california medicaid program. J Allergy Clin Immunol Pract 9(1):375–384e5CrossRefPubMed Palmsten K, Bandoli G, Watkins J et al (2021) Oral corticosteroids and risk of preterm birth in the california medicaid program. J Allergy Clin Immunol Pract 9(1):375–384e5CrossRefPubMed
41.
Zurück zum Zitat Strouse J, Donovan BM, Fatima M et al (2019) Impact of autoimmune rheumatic diseases on birth outcomes: a population-based study. RMD Open 5(1):e878CrossRefPubMedPubMedCentral Strouse J, Donovan BM, Fatima M et al (2019) Impact of autoimmune rheumatic diseases on birth outcomes: a population-based study. RMD Open 5(1):e878CrossRefPubMedPubMedCentral
42.
Zurück zum Zitat Berard A, Sheehy O, Girard S et al (2018) Risk of preterm birth following late pregnancy exposure to NSAIDs or COX‑2 inhibitors. Pain 159(5):948–955CrossRefPubMed Berard A, Sheehy O, Girard S et al (2018) Risk of preterm birth following late pregnancy exposure to NSAIDs or COX‑2 inhibitors. Pain 159(5):948–955CrossRefPubMed
43.
Zurück zum Zitat Sammaritano LR, Bermas BL, Chakravarty EE et al (2020) 2020 American College of Rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases. Arthritis Rheumatol 72(4):529–556CrossRefPubMed Sammaritano LR, Bermas BL, Chakravarty EE et al (2020) 2020 American College of Rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases. Arthritis Rheumatol 72(4):529–556CrossRefPubMed
44.
Zurück zum Zitat Flint J, Panchal S, Hurrell A et al (2016) BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-Part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids. Rheumatology 55(9):1693–1697CrossRefPubMed Flint J, Panchal S, Hurrell A et al (2016) BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-Part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids. Rheumatology 55(9):1693–1697CrossRefPubMed
45.
Zurück zum Zitat Flint J, Panchal S, Hurrell A et al (2016) BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-Part II: analgesics and other drugs used in rheumatology practice. Rheumatology 55(9):1698–1702CrossRefPubMed Flint J, Panchal S, Hurrell A et al (2016) BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-Part II: analgesics and other drugs used in rheumatology practice. Rheumatology 55(9):1698–1702CrossRefPubMed
46.
Zurück zum Zitat Perez-Garcia LF, Te Winkel B, Carrizales JP et al (2020) Sexual function and reproduction can be impaired in men with rheumatic diseases: A systematic review. Semin Arthritis Rheum 50(3):557–573CrossRefPubMed Perez-Garcia LF, Te Winkel B, Carrizales JP et al (2020) Sexual function and reproduction can be impaired in men with rheumatic diseases: A systematic review. Semin Arthritis Rheum 50(3):557–573CrossRefPubMed
47.
Zurück zum Zitat Weber-Schoendorfer C, Hoeltzenbein M, Wacker E et al (2014) No evidence for an increased risk of adverse pregnancy outcome after paternal low-dose methotrexate: an observational cohort study. Rheumatology 53(4):757–763CrossRefPubMed Weber-Schoendorfer C, Hoeltzenbein M, Wacker E et al (2014) No evidence for an increased risk of adverse pregnancy outcome after paternal low-dose methotrexate: an observational cohort study. Rheumatology 53(4):757–763CrossRefPubMed
48.
Zurück zum Zitat Wallenius M, Lie E, Daltveit AK et al (2015) No excess risks in offspring with paternal preconception exposure to disease-modifying antirheumatic drugs. Arthritis Rheumatol 67(1):296–301CrossRefPubMed Wallenius M, Lie E, Daltveit AK et al (2015) No excess risks in offspring with paternal preconception exposure to disease-modifying antirheumatic drugs. Arthritis Rheumatol 67(1):296–301CrossRefPubMed
49.
Zurück zum Zitat Viktil KK, Engeland A, Furu K (2012) Outcomes after anti-rheumatic drug use before and during pregnancy: a cohort study among 150,000 pregnant women and expectant fathers. Scand J Rheumatol 41(3):196–201CrossRefPubMed Viktil KK, Engeland A, Furu K (2012) Outcomes after anti-rheumatic drug use before and during pregnancy: a cohort study among 150,000 pregnant women and expectant fathers. Scand J Rheumatol 41(3):196–201CrossRefPubMed
50.
Zurück zum Zitat Espinosa G, Galindo-Izquierdo M, Marcos Puig B et al (2021) Pregnancy control in patients with systemic lupus erythematosus and antiphospholipid syndrome. Part 1: infertility, ovarian preservation and preconception assessment. Consensus document of the Spanish society of Gynaecology and obstetrics (SEGO), the Spanish society of internal medicine (SEMI) and the Spanish society of rheumatology (SER). Reumatol Clin 17(2):61–66CrossRefPubMed Espinosa G, Galindo-Izquierdo M, Marcos Puig B et al (2021) Pregnancy control in patients with systemic lupus erythematosus and antiphospholipid syndrome. Part 1: infertility, ovarian preservation and preconception assessment. Consensus document of the Spanish society of Gynaecology and obstetrics (SEGO), the Spanish society of internal medicine (SEMI) and the Spanish society of rheumatology (SER). Reumatol Clin 17(2):61–66CrossRefPubMed
51.
Zurück zum Zitat Rodriguez Almaraz E, Saez-Comet L, Casellas M et al (2021) Pregnancy control in patients with systemic lupus erythematosus/antiphospholipid syndrome. Part 2: Pregnancy follow-up. Reumatol Clin 17(3):125–131CrossRefPubMed Rodriguez Almaraz E, Saez-Comet L, Casellas M et al (2021) Pregnancy control in patients with systemic lupus erythematosus/antiphospholipid syndrome. Part 2: Pregnancy follow-up. Reumatol Clin 17(3):125–131CrossRefPubMed
52.
Zurück zum Zitat Delgado P, Robles A, Martinez Lopez JA et al (2021) Pregnancy control in patients with systemic lupus erythematosus/Antiphospholipid syndrome. Part 3: childbirth. Puerperium. Breastfeeding contraception. Newborn. Reumatol Clin 17(4):183–186CrossRefPubMed Delgado P, Robles A, Martinez Lopez JA et al (2021) Pregnancy control in patients with systemic lupus erythematosus/Antiphospholipid syndrome. Part 3: childbirth. Puerperium. Breastfeeding contraception. Newborn. Reumatol Clin 17(4):183–186CrossRefPubMed
53.
Zurück zum Zitat Tektonidou MG, Andreoli L, Limper M et al (2019) EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis 78(10):1296–1304CrossRefPubMed Tektonidou MG, Andreoli L, Limper M et al (2019) EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis 78(10):1296–1304CrossRefPubMed
54.
Zurück zum Zitat Andreoli L, Bertsias GK, Agmon-Levin N et al (2017) EULAR recommendations for women’s health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis 76(3):476–485CrossRefPubMed Andreoli L, Bertsias GK, Agmon-Levin N et al (2017) EULAR recommendations for women’s health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis 76(3):476–485CrossRefPubMed
55.
Zurück zum Zitat Jethwa H, Lam S, Smith C et al (2019) Does rheumatoid arthritis really improve during pregnancy? A systematic review and metaanalysis. J Rheumatol 46(3):245–250CrossRefPubMed Jethwa H, Lam S, Smith C et al (2019) Does rheumatoid arthritis really improve during pregnancy? A systematic review and metaanalysis. J Rheumatol 46(3):245–250CrossRefPubMed
56.
Zurück zum Zitat Blagojevic J, AlOdhaibi KA, Aly AM et al (2020) Pregnancy in systemic sclerosis: results of a systematic review and metaanalysis. J Rheumatol 47(6):881–887CrossRefPubMed Blagojevic J, AlOdhaibi KA, Aly AM et al (2020) Pregnancy in systemic sclerosis: results of a systematic review and metaanalysis. J Rheumatol 47(6):881–887CrossRefPubMed
57.
Zurück zum Zitat Maguire S, O’Dwyer T, Mockler D et al (2020) Pregnancy in axial spondyloarthropathy: a systematic review & meta-analysis. Semin Arthritis Rheum 50(6):1269–1279CrossRefPubMed Maguire S, O’Dwyer T, Mockler D et al (2020) Pregnancy in axial spondyloarthropathy: a systematic review & meta-analysis. Semin Arthritis Rheum 50(6):1269–1279CrossRefPubMed
58.
Zurück zum Zitat Andreoli L, Gerardi MC, Fernandes M et al (2019) Disease activity assessment of rheumatic diseases during pregnancy: a comprehensive review of indices used in clinical studies. Autoimmun Rev 18(2):164–176CrossRefPubMed Andreoli L, Gerardi MC, Fernandes M et al (2019) Disease activity assessment of rheumatic diseases during pregnancy: a comprehensive review of indices used in clinical studies. Autoimmun Rev 18(2):164–176CrossRefPubMed
Metadaten
Titel
Erkenntnisse zu Schwangerschaft und Stillzeit bei entzündlich rheumatischen Erkrankungen durch Beobachtungsdaten
verfasst von
Dr. Yvette Meißner
PD Dr. med. Anja Strangfeld
Publikationsdatum
17.09.2021
Verlag
Springer Medizin
Erschienen in
Zeitschrift für Rheumatologie / Ausgabe 8/2021
Print ISSN: 0340-1855
Elektronische ISSN: 1435-1250
DOI
https://doi.org/10.1007/s00393-021-01082-4

Weitere Artikel der Ausgabe 8/2021

Zeitschrift für Rheumatologie 8/2021 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.